Shionogi
Shionogi & Co., Ltd., commonly known as Shionogi, is a prominent pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, Shionogi has established itself as a leader in the pharmaceutical industry, focusing on research and development in areas such as infectious diseases, pain management, and central nervous system disorders.
With a strong presence in Japan and expanding operations in North America and Europe, Shionogi is renowned for its innovative core products, including antiviral treatments and analgesics. The company’s commitment to advancing healthcare solutions has led to significant milestones, including the development of groundbreaking therapies that address unmet medical needs.
Shionogi's dedication to quality and innovation has positioned it as a key player in the global pharmaceutical market, earning recognition for its contributions to public health and patient care.
+22 vs industry average
Shionogi’s score of 60 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Shionogi?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Shionogi's reported carbon emissions
In 2024, Shionogi & Co., Ltd. reported total carbon emissions of approximately 242.2 million kg CO2e. This figure includes Scope 1 emissions of about 40.1 million kg CO2e, Scope 2 emissions of approximately 22.9 million kg CO2e (market-based), and significant Scope 3 emissions of around 179.2 million kg CO2e, primarily from purchased goods and services. Shionogi has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by FY2030/31 from a FY2019/20 baseline. Additionally, the company targets a 20% reduction in Scope 3 emissions from purchased goods and services within the same timeframe. By 2050, Shionogi aims to achieve net-zero emissions across all scopes. These targets align with the Science Based Targets initiative (SBTi) and reflect Shionogi's commitment to addressing climate change within the pharmaceutical sector. The company is actively working towards these goals, with specific initiatives to reduce Scope 1 and 2 emissions to near zero by the mid-2020s.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Shionogi’s Climate Goals (2030 & 2050)
4 goals2035
46.2% reduction in all scopes
【GHG排出抑制】(2019年度基準) 2030年度 46.2%削減 2035年度 60%削減 カーボンニュートラル 再生可能エネルギー由来 電力導入率90%以上
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 4 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
3 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsFrequently asked questions
Common questions about Shionogi’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project